The drugmaker paused work on MM-310, a cancer treatment, after observing signs of peripheral neuropathy in clinical trial participants. Discontinuation of the cancer treatment development comes six months after Merrimack shelved production of a different cancer drug.
As a result, the drugmaker plans to lay off an undisclosed number of its 27 employees.
The company said it will invest resources toward development of its two preclinical drug candidates.
Read the full report here.
More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25
